The estimated Net Worth of Mahiuddin Ahmed is at least $6.3 Milhão dollars as of 26 May 2020. Mahiuddin Ahmed owns over 50,000 units of Y-Mabs Therapeutics Inc stock worth over $1,990,500 and over the last 5 years he sold YMAB stock worth over $4,310,306. In addition, he makes $0 as Senior Vice President e Chief Scientific Officer at Y-Mabs Therapeutics Inc.
Mahiuddin has made over 4 trades of the Y-Mabs Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of YMAB stock worth $1,969,000 on 26 May 2020.
The largest trade he's ever made was selling 50,000 units of Y-Mabs Therapeutics Inc stock on 26 May 2020 worth over $1,969,000. On average, Mahiuddin trades about 27,500 units every 4 days since 2020. As of 26 May 2020 he still owns at least 150,000 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mahiuddin Ahmed stock trades at the bottom of the page.
Dr. Mahiuddin Ahmed Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. Dr. Ahmed joined our Company in March 2018 as Vice President and Chief Scientific Officer and since January 1, 2020 has been Senior Vice President and Chief Scientific Officer. Dr. Ahmed is an expert in antibody and therapeutic protein engineering based on in silico design. He received his Ph.D in Biochemistry and Structural Biology from Stony Brook University and completed postdoctoral training in cancer immunotherapy at the Sloan Kettering Institute. He was formerly a faculty member in the Department of Pediatrics at Memorial Sloan Kettering and is an inventor of numerous issued and pending patents related to therapeutic proteins, bispecific antibodies, radioimmunotherapy products and related technologies. Dr. Ahmed oversees our Research & Development Laboratories in Nutley, New Jersey.
Mahiuddin Ahmed is 41, he's been the Senior Vice President e Chief Scientific Officer of Y-Mabs Therapeutics Inc since 2020. There are 18 older and no younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Mahiuddin's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad, eJohan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: